Recent Developments in Heterocyclic Derivatives as Novel Cancer Therapeutics: From 2020-2024

Area of Science:

• Medicinal Chemistry
• Drug Discovery
• Oncology

Background:

• Cancer remains a leading global cause of mortality, necessitating continuous improvement in therapeutic strategies.
• Heterocyclic moieties are crucial scaffolds in drug discovery due to their structural versatility and biological target interactions.
• Heteroatoms within these cyclic compounds modulate key cellular pathways involved in tumor progression, apoptosis, and proliferation.

Purpose of the Study:

• To comprehensively analyze the role of heterocyclic moieties in anticancer drug development.
• To review the latest advances and future prospects in this rapidly progressing field.
• To contribute to the design of more effective and targeted cancer therapies.

Main Methods:

• Review of existing literature on heterocyclic compounds in anticancer drug discovery.
• Analysis of structural modifications and hybridization strategies for enhanced activity.
• Exploration of computational modeling and advanced drug delivery systems.

Main Results:

• Hybridization of aromatic and non-aromatic rings in heterocyclic structures yields derivatives with enhanced anticancer activity, selectivity, and reduced adverse effects.
• Heterocyclic derivatives show significant potential in modulating tumor progression, apoptosis, and proliferation.
• Integration of computational modeling and advanced delivery systems improves therapeutic potential.

Conclusions:

• Heterocyclic moieties are indispensable in modern anticancer drug development.
• Continued research into molecular frameworks, computational design, and delivery systems will drive future therapeutic advancements.
• This review provides a summary of key findings and emerging trends to guide the development of next-generation cancer therapies.